OR WAIT null SECS
© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Best practices for the use of gene profiling assays to guide treatment decisions for patients with early-stage HR-positive breast cancer.
May 19th 2021
Goals and standards of care for therapy in patients with early-stage HR-positive breast cancer.
Considerations for therapeutic decision-making in adjuvant and neoadjuvant settings in early-stage HR-positive breast cancer.
May 20th 2021
The role of gene profiling assays in identifying candidates for chemotherapy in early HR-positive breast cancer.
Results of 2 prospective, randomized clinical trials of the Oncotype DX Breast Recurrence Score and implications for practice.
May 21st 2021
Considerations for using gene profiling assays to identify appropriate patients for neoadjuvant therapy in early-stage HR-positive breast cancer.
Debu Tripathy, MD, of the University of Texas MD Anderson Cancer Center, comments on current NCCN recommendations for the use of prognostic and predictive gene profiling assays to individualize treatment in patients with HR-positive breast cancer.
May 22nd 2021
Kevin Kalinsky, MD, MS, of Emory Winship Cancer Institute, discusses treatment options for HR-positive/HER2-negative breast cancer and comments on the evolving role of genomic testing in regard to treatment selection.
Dr Kevin Kalinsky describes when and for whom neoadjuvant therapy may be appropriate for the management of HR-positive breast cancer.
May 27th 2021
The value of utilizing a genomic test to help guide decisions for adjuvant therapy for HR-positive breast cancer.
A discussion on the types of information provided by genetic tests and genomic assays and recommendations for use in HR-positive breast cancer.